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INTRODUCTION
While adoptive immunotherapy holds promise as a treatment for cancer, development of adoptive immunotherapy has been impeded by the lack of a reproducible and economically viable method for generating therapeutic numbers of antigen-specific CTL. Therefore, we are studying use of HLA A2-Ig based aAPC for induction and expansion of prostate specific CTL with the goal of replacing the use of autologous DC for adoptive immunotherapy for prostate cancer. More specifically, we will demonstrate functional efficacy of an "off the shelf" HLA-Ig based artificial Antigen Presenting Cells (aAPC) for inducing and expanding anti-EphA2(58) or PSMA 27 prostate-specific CTL. The specific aims are to 1) optimize aAPC structure and duration of stimulation, and 2) analyze the in vivo function of aAPC-induced CTL. These studies will serve as precursor ones for induction and expansion of prostate specific CTL from patients with disease for initiation of adoptive immunotherapy clinical studies as an adjuvant therapy post surgery in the setting of minimal residual disease.
BODY
Adoptive immunotherapy for prostate cancer has been limited by the use of autologous dendritic cells (DC) for expansion of prostate cancer-specific CTL. Recently, we have shown that HLA-A2-Ig based aAPC can be used to expand model antigen specific CTL. To evaluate this approach for use in prostate cancer immunotherapy we proposed to study initially aAPC based in vitro expansion of prostate cancer specific CTL using blood from healthy donors and later to evaluate the in vivo efficacy of these CTL using a human/SCID mouse model. Over the past award time we have focused on our goals as identified in the statement of work, specifically on optimization of aAPC based T cell stimulation and induction of EphA2 and PSMA specific CTL.
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In vitro characterization: - 51 Cr release assay -dimer staining Legend: CD8 + T cells were isolated from peripheral blood of healthy donors using magnetic CD8 -depletion and co-cultured as shown in the schematic for 4-6 weeks. CD8 + T cells were co-cultured with peptide loaded aAPC and harvested once a week. The old beads were removed; T cells were counted and replated and restimulated in 96 well plates with fresh aAPC. After 3 weeks cells were tested as described. Cultures were maintained until the total cell count dropped below 5x10 5 .
We performed aAPC stimulation as described in Figure 1 for multiple donors with PSMA, EphA2 and control peptides like CMV or Mart-1. After several weeks of culture we were able to detect EphA2 specific T cells from 3 donors, whereas no PSMA specific T cells could be generated. At the same time control cultures using Mart-1 or CMV loaded aAPC generated large numbers of highly specific T cells. Figure 2 shows one representative example. The specificity and functionality of the EphA2-specific CTL was confirmed by specific lyses of peptide pulsed target cells in an 51 Cr-release assay (Figure 3 ).
D22 -EphA2
CD8 FITC Since the initial approach was not successful for generation of PSMA specific CTL and the generation of EphA2-specific CTL was limited in numbers, we have started to develop second generation aAPC formulations as proposed in the statement of work. B7.1 (CD80) and B7.2 (CD86) on DC are the natural ligands to CD28 on T cells. In addition, it has been reported that the engagement of CD83 on DC with his currently still unknown ligand on T cells can support proliferation and at the same time reduce T cell apoptosis. Our standard aAPC was made by using HLA-A2-Ig in combination with an antibody specific for CD28 on T cells. We postulated Legend: Figure 2 shows dimer/tetramer staining of T cells which were stimulated for 3 weeks with A) EphA2 loaded aAPC, B) PSMA loaded aAPC and C) CMV loaded aAPC. While the CMV loaded aAPC induced high numbers of antigen specific CTL, aAPC loaded with the prostate cancer specific peptides induce only small numbers using the EphA2 peptide and no specific T cells using the PSMA peptide.
that the natural ligand might have higher affinity or activity and therefore might induce better or stronger costimulation. Effector : Target ratio % specific lysis Therefore, we created new aAPC by coating B7.1, B7.2 or B7.1 and B7.2 together with HLA-A2-Ig on magnetic beads. In addition we also generated aAPC by coating magnetic beads with HLA-A2-Ig in combination with CD83-Ig +/-anti-CD28. Figure 4 shows a schematic of the new created aAPC.
To investigate these new systems we compared the stimulation of the new aAPC with our prototype anti-CD28 based aAPC in either the Mart-1 or in case of the CD83-based aAPC in the CMV system. Both are robust systems which work well for induction of functional antigenspecific CTL as shown in our previous work(1, 2).
We found that in 2 of 3 experiments B7-1 based aAPC generated a higher frequency of antigenspecific CTL than our standard aAPC, figure 5 shows one representative experiment. For one donor we also found a much higher proliferation compared to all other aAPC formulations tested (data not shown).
Legend: Figure 3 shows the cytotoxic activity of aAPC induced peptide specific CTL. CD8 + T cells were stimulated for 3 weeks with either EphA2 loaded aAPC (A), PSMA loaded aAPC (B) or CMV loaded aAPC (C) and then tested for their cytotoxic activity using a standard 51 Crrelease assay. Therefore, total T cells were incubated with either peptide loaded target cells or unloaded target cells as negative control. The given ratios are the ratios from total T cells to target cells. Based on these results we have repeated the experiments to induce prostate cancer specific CTL, comparing our standard anti-CD28 based aAPC with the B7.1-Ig based aAPC ( Figure 6 ). We found that in the first 2 experiments that the use of B7.1-Ig based aAPC did not improve the outcome of the resulting T cell product. While the FACS analysis using antigen-specific dimer staining showed the induction of EphA2-specific CTL at comparable levels to our standard aAPC ( Figure 6A ), further functional analysis showed high non-specific killing for CTL that were induced with B7.1-Ig based aAPC. In contrast CTL which were induced with our regular anti-CD28 aAPC showed only minimal non-specific killing ( Figure 6B ). This could be due to the high amount of non-EphA2-spepcific cells contaminating the culture. Therefore, further experiments, which are currently ongoing, are necessary to analyze the capacity of the B7.1-Ig based aAPC in more detail. This is specifically important these aAPC seemed to be more potent in the well established Mart-1 system.
Puetz CD28 Mart-1 tetramr .009 To evaluate the new CD83-Ig based aAPC we used the CMV system. We performed 3 experiments to generate CMV specific CTL from CD8+ T cells of healthy donors and compared the results with the use of our standard aAPC. The results show that the new aAPC are fully functional and capable of inducing antigen specific CTL.
Unfortunately, no major differences in specificity or expansion of the expanded T cells were detected when these new CD83-Ig based aAPC were compared with our current standard anti-CD28 based aAPC. Figure 7 shows one representative experiment. The fact that we were not able to major differences between the old and new aAPC could be due to the fact that the CMV system is such a strong antigen which does not require costimulation. Therefore, it is quite possible that we will detect differences when we will use these new aAPC to induce EphA2-specific CTL.
Legend: Figure 5 shows the analysis of the EphA2-specific CTL which were induced with B7.1-Ig based aAPC in comparison with EphA2-specific CTL induced with our current standard anti-CD28 based aAPC. In A is shown the tetramer analysis and in B is shown the result of the cytotoxic activity of the different EphA2-specific CTL lines determined with a standard 51 Crrelease assay. The effector target ratios are calculated according to the Total T cell number. In addition to varying the type of costimulation we have also modified the ratio of signal 1 to signal 2 on our standard aAPC by preparing aAPC in the presence of different amounts of protein, as proposed in the statement of work. We have prepared a total of 4 different types of aAPC, by using the following ratio of HLA-A2-Ig to anti-CD28 (1:0, 8:2, 1:1, and 2:8). Figure 8 shows the results of our initial experiments, in which we used the different aAPC batches to generate CMV-specific CTL. While the CMV system is ideal to test the functionality of the new aAPC it seems it is to robust to identify differences in the stimulation capacity of the aAPC batches. Experiments to analyze the stimulation potential for EphA2-specific CTL are on going.
To overcome the problem of the limited expansion of the prostate cancer specific T cells we studied two approaches a) we used dimer and aAPC based antigen-specific T cell sorting to enrich, clone and expand prostate cancer-specific CTL and b) we studied the potential of aAPC immunization to activate and expand tumor-specific CTL in vivo.
Legend: Figure 7 shows the dimer staining analysis of CMV specific CTL which were induced from CD8+ T cell of healthy donors using new aAPC made by coupling CD83-Ig +/-anti-CD28 together with HLA-A2-Ig onto magnetic beads. The result shows that all beads are functional, no major differences were seen between our standard anti-CD28 based aAPC and the new CD83-Ig based aAPC. While we have expanded more than 30 potential T cell clones using a cloning protocol which we have previously successful established using influenza M1 specific CTL (Figure 9 ), we were not able to generate EphA2-specific clones.
In our second approach we studied the effect of aAPC immunization to activate antigenspecific T cells in vivo. As schematically shown in Figure 10A , we have utilized a murine model in which we injected 5x10 5 genetically modified SIY-pepitde expressing B16 tumor cells (B16.SIY) s.c. into B6 mice (day -7) to induce a solid tumor. Once the tumor had reached a size of ~5 mm diameter (day 0), 3x10 6 naïve SIY-specific T cells from 2C-TCR transgenic mice were adoptively transferred (i.v.). On days 1-3, we i.v. injected the mice with either 10 7 cognate or non-cognate aAPC and followed the tumor growth closely. As shown in Figure 10B , there was no statistically significant influence of treatment with non-cognate aAPC when compared to Legend: Figure 8 shows the CMV tetramer analysis of CMV specific CTL which were generated with aAPC which were made by coupling different amounts of HLA-A2-Ig and anti-CD28 onto a magnetic bead. The ration of signal 1 to signal 2 used for the aAPC preparation is shown in the title of each individual density plot. As negative control we stained the T cells with a PE labeled Mart-1 tetramer. Legend: Figure 9 shows the tetramer analysis of flu-M1-specific CTL pre and post cloning. The left hand side shows analysis of the aAPC enriched bulk culture and on the right hand side is shown the analysis of one representative CTL clone. As negative control staining with the nonspecific CMV-tetramer was used.
KEY RESEARCH ACCOMPLISHMENTS
• aAPC can be used to induce functional active prostate cancer specific CTL.
• Development of 2 nd generation aAPC using multiple costimulatory molecules and different ratios of HLA-Ig to the costimulatory molecule. + T cells and peptide aAPCs measured over 22 days at 2-3 day intervals. Tumor growth curves for mice treated with SIY-aAPC show statistically significant differences compared to mice that were untreated or treated with β-Gal loaded aAPCs. Error bars represent the standard error of the mean (n=5).
• While some variations from donor to donor and antigen to antigen were observed it seems that the engagement of CD28 with his natural ligand B7.1-Ig, on 2 nd generation aAPC, instead of a mAb specific for CD28 can result in better stimulation and expansion of antigen-specific CTL. More detailed experiments are necessary to confirm initial results.
• aAPC as well as dimer technology can be used to enrich for antigen specific CTL.
• aAPC immunization can be used to activate antigen specific T cells in vivo, thus this technology might be used to overcome limitations and hurdles related to in vitro culture of antigen-specific T cells such as limited expansion and GMP requirements for in vitro culture.
REPORTABLE OUTCOMES
A manuscript describing the use of peptide loaded aAPC for generation and cloning of prostate cancer specific CTL is in preparation. Another manuscript including the aAPC immunization data is currently submitted to the Journal "Cancer Research".
CONCLUSION
In summary, the performed experiments have resulted in the generation of prostate cancer specific CTL. We have further developed a large variety of 2 nd generation aAPC which, while functional proven active; need to be further evaluated by using the low affinity prostate cancer specific antigens EphA2 and PSMA. These results will permit us to move effectively and clearly into evaluation of the in vivo efficacy of aAPC expanded prostate cancer specific T cells. In addition while our attempts to clone EphA2 specific CTL have so far not succeeded, we have studied the potential of aAPC immunization for in vivo activation of antigen specific T cells and found that aAPC can be used to stimulate tumor-specific T cells in vivo resulting in significant delay in tumor growth. Therefore, this new approach can be used to overcome the needs of large scale in vitro expansion of tumor specific T cells. Thus in future experiments we will test the possibility to adoptively transfer smaller numbers of antigen-specific CTL after short in vitro culture and then boost these cells in vivo using aAPC immunization. Such an approach has the additional advantage of limited in vitro expansion which will reduce cost and labor and more importantly prevent the expanded T cells from exhaustion due to long term in vitro culture.
